患者参与药物监管的国际经验与启示

邬镜净; 曾凯欣; 杨雨菲; 田梦妍; 董方正; 张怡萌; 李军; 茅宁莹

doi:10.6039/j.issn.1001-0408.2025.08.03

您当前的位置：

首页 >

文章列表页 >

患者参与药物监管的国际经验与启示

药事管理 | 更新时间：2025-09-23

- 患者参与药物监管的国际经验与启示
- International experience and enlightenment of patient engagement in drug regulation
- 中国药房 2025年36卷第8期页码：908-913
- 作者机构：
  
  1.中国药科大学国际医药商学院，南京　211198
  2.中国药科大学国家药物政策与医药产业经济研究中心，南京　211198
- 作者简介：
  
  硕士研究生。研究方向：社会与管理药学。E-mail：Wujingjing_0721@163.com
  教授，博士生导师。研究方向：医药产业政策。E-mail：mny523@126.com
- 基金信息：
  
  江苏省社会科学基金一般专项资助项目(22JZB002);江苏省高校哲学社会科学研究项目(2021SJA0075);江苏高校哲学社会科学研究重大项目(2024SJZD128);2024年江苏省研究生科研创新计划(KYCX24_1050)
- DOI：10.6039/j.issn.1001-0408.2025.08.03
  中图分类号： R95
- 收稿日期：2024-09-30，
  
  修回日期：2025-01-10，
  
  录用日期：2025-01-10，
  
  纸质出版日期：2025-04-30
- 稿件说明：
移动端阅览
邬镜净,曾凯欣,杨雨菲,等.患者参与药物监管的国际经验与启示 [J].中国药房,2025,36(08):908-913.

WU Jingjing,ZENG Kaixin,YANG Yufei,et al.International experience and enlightenment of patient engagement in drug regulation[J].ZHONGGUO YAOFANG,2025,36(08):908-913.
邬镜净,曾凯欣,杨雨菲,等.患者参与药物监管的国际经验与启示 [J].中国药房,2025,36(08):908-913. DOI： 10.6039/j.issn.1001-0408.2025.08.03.

WU Jingjing,ZENG Kaixin,YANG Yufei,et al.International experience and enlightenment of patient engagement in drug regulation[J].ZHONGGUO YAOFANG,2025,36(08):908-913. DOI： 10.6039/j.issn.1001-0408.2025.08.03.

摘要

目的

为完善我国患者参与药物监管的路径和体系建设提供建议。

方法

通过梳理美国、欧盟和日本等国家或地区促进患者参与药物监管的举措和经验，总结国际上患者在药物监管全过程中的角色扮演和作用发挥，再结合我国患者参与药物监管的发展现状和现存挑战，提出完善我国患者参与药物监管路径和体系建设的具体建议。结果与

结论

随着国际上不断提升对患者参与药物监管这一策略的重视程度，美国、欧盟和日本等国家或地区在患者参与药物监管方面出台了较为明晰的政策法规并设置了专管部门，形成了多样化的患者参与药物监管的路径和模式，患者可以通过研讨会议或直接参与决策等形式参与到药物监管环节中，用自身体验和专业知识对药物监管流程进行优化。目前，我国的患者参与药物监管工作尚处于以临床价值为导向的药物研发层面，也未出台指导患者参与药物监管的政策文件。建议我国在现有政策体系的基础上，进一步加强患者参与保障体系建设，完善患者参与药物监管的能力建设和路径模式，推动我国患者参与药物监管持续向前发展。

Abstract

OBJECTIVE

To provide suggestions for improving the path and system construction of patient engagement in drug regulation in China.

METHODS

By reviewing initiatives and experiences from the United States （U. S.）， European Union （EU）， and Japan in promoting patient engagement， this study summarizes the roles and contributions of patients in the entire drug regulatory process internationally. Combining China’s current progress and challenges in patient engagement， specific proposals are formulated to refine regulatory pathways and institutional systems.

RESULTS &

CONCLUSIONS

With growing global emphasis on patient engagement as a regulatory strategy， countries or regions such as the U.S.， EU， and Japan have established clear policies， designated oversight agencies， and developed diversified pathways for patient engagement. Patients contribute to regulatory processes through advisory meetings， direct decision-making roles， and leveraging lived experiences and expertise to optimize drug evaluation and monitoring. In contrast， China’s patient engagement remains primarily limited to clinical value-oriented drug development， lacking formal policy guidance. It is recommended that China， based on its existing policy system， further strengthen the construction of a safeguard system for patient engagement， improve the capacity building and pathway models for patient participation in pharmaceutical regulation， and promote the continuous development of patient engagement in pharmaceutical regulation in our country.

关键词

Keywords

references

HOOS A ， ANDERSON J ， BOUTIN M ， et al . Partnering with patients in the development and lifecycle of medicines：a call for action [J ] . Ther Innov Regul Sci ， 2015 ， 49 （ 6 ）： 929 - 939 .

BRITTEN N . Medication errors：the role of the patient [J ] . Br J Clin Pharmacol ， 2009 ， 67 （ 6 ）： 646 - 650 .

Council for International Organizations of Medical Scien-ces . Patient involvement in the development，regulation and safe use of medicines [R/OL ] .[ 2025-01-09 ] . https：//cioms.ch/publications/product/patient-involvement/ https://cioms.ch/publications/product/patient-involvement/ .

蒋玉霞，茅宁莹 . 欧盟促进患者参与药物研发的实践及对我国的启示 [J ] . 中国新药杂志， 2019 ， 28 （ 19 ）： 2312 - 2318 .

徐筱蕾，贺宇杉，李军 . “患者参与” 理念内涵及形成过程概述 [J ] . 中华医院管理杂志， 2018 ， 34 （ 5 ）： 396 - 399 .

Office of Pharmaceutical Industry Research . Thinking about “patient and public involvement” in the healthcare field [EB/OL ] . （ 2023-03-25 ）[ 2025-01-09 ] . https：//www.jpma.or.jp/opir/news/058/01.html https://www.jpma.or.jp/opir/news/058/01.html .

KISH L . Patient engagement is a strategy，not a tool [R/OL ] . [ 2025-01-09 ] . https：//hl7standards.com/wp-content/themes/vrxari5pwd76ek0nilkdf102400/files/wp-content/uploads/2014/11/hl7standards-patient-engagement-ebook.pdf https://hl7standards.com/wp-content/themes/vrxari5pwd76ek0nilkdf102400/files/wp-content/uploads/2014/11/hl7standards-patient-engagement-ebook.pdf .

The European Patients’ Academy . Guidance for patient involvement in regulatory processes [EB/OL ] .（ 2023-07-18 ）[ 2024-09-18 ] . https：//toolbox.eupati.eu/resources/patient-toolbox/guidance-for-patient-involvement-in-regulatory-processes/ https://toolbox.eupati.eu/resources/patient-toolbox/guidance-for-patient-involvement-in-regulatory-processes/ .

方中坚，沈家辉，汪颖霞，等 . 以患者为中心的临床试验理念及发展趋势探讨 [J ] . 中国新药杂志， 2024 ， 33 （ 13 ）： 1356 - 1361 .

吴晓蕾，史梦龙，张晨瑶，等 . 以患者为中心药物研发相关概念介绍 [J ] . 中国循证医学杂志， 2023 ， 23 （ 12 ）： 1472 - 1477 .

DIA Global Forum . Patient engagement that enables regulatory decisions [EB/OL ] . （ 2023-03-04 ）[ 2024-11-05 ] . https：//globalforum.diaglobal.org/issue/february-2023/patient-engagement-that-enables-regulatory-decisions/ https://globalforum.diaglobal.org/issue/february-2023/patient-engagement-that-enables-regulatory-decisions/ .

晏利姣，杨思红， HU X Y ，等 . 如何在临床实践指南制定过程中保证患者及公众的有效参与 [J ] . 中国循证心血管医学杂志， 2022 ， 14 （ 9 ）： 1025 - 1028 .

FDA . Training and development initiatives [EB/OL ] . （ 2019-04-10 ）[ 2024-11-05 ] . https：//www.fda.gov/science-research/fda-stem-outreach-education-and-engagement/training-and-development-initiatives https://www.fda.gov/science-research/fda-stem-outreach-education-and-engagement/training-and-development-initiatives .

EMA . Mandate，objectives and composition of the Patients and Consumers Working Party （PCWP） [EB/OL ] . （ 2019-05-10 ）[ 2024-09-18 ] . https：//www.ema.europa.eu/en/documents/other/mandate-objectives-composition-patients-consumers-working-party-pcwp_en.pdf https://www.ema.europa.eu/en/documents/other/mandate-objectives-composition-patients-consumers-working-party-pcwp_en.pdf .

PMDA . Patient centricity WG [EB/OL ] . （ 2019-05-01 ）[ 2024-09-18 ] . https：//www.pmda.go.jp/english/rs-sb-std/rs/0022.html https://www.pmda.go.jp/english/rs-sb-std/rs/0022.html .

Around the Globe . Assessing the scope of patient engagement in Canada [EB/OL ] . [ 2024-09-18 ] . https：//globalforum.diaglobal.org/issue/june-2020/assessing-the-scope-of-patient-engagement-in-canada/ https://globalforum.diaglobal.org/issue/june-2020/assessing-the-scope-of-patient-engagement-in-canada/ .

FDA . Condition-specific meeting reports and other information related to patients’ experience [EB/OL ] .[ 2024-11-05 ] . https：//www.fda.gov/industry/prescription-drug-user-fee-amendments/condition-specific-meeting-reports-and-other-information-related-patients-experience https://www.fda.gov/industry/prescription-drug-user-fee-amendments/condition-specific-meeting-reports-and-other-information-related-patients-experience .

MURPHY A ， BERE N ， VAMVAKAS S ， et al . The added value of patient engagement in early dialogue at EMA： scientific advice as a case study [J ] . Front Med （Lausanne）， 2022 ， 8 ： 811855 .

FDA . Patient engagement collaborative [EB/OL ] . （ 2023-08-14 ）[ 2024-09-18 ] . https：//www.fda.gov/patients/learn-about-fda-patient-engagement/patient-engagement-colla-borative https://www.fda.gov/patients/learn-about-fda-patient-engagement/patient-engagement-colla-borative .

FDA . About the FDA patient representative program [EB/OL ] . （ 2023-12-04 ）[ 2024-09-18 ] . https：//www.fda.gov/patients/learn-about-fda-patient-engagement/about-fda-patient-representative-program https://www.fda.gov/patients/learn-about-fda-patient-engagement/about-fda-patient-representative-program .

FDA . Charter of the Patient Engagement Advisory Committee to the Food and Drug Administration [EB/OL ] .（ 2023-10-05 ）[ 2024-09-18 ] . https：//www.fda.gov/advisory-committees/patient-engagement-advisory-committee/charter-patient-engagement-advisory-committee-food-and-drug-administration https://www.fda.gov/advisory-committees/patient-engagement-advisory-committee/charter-patient-engagement-advisory-committee-food-and-drug-administration .

EMA . How the European Medicines Agency interacts with patients and consumers [EB/OL ] . （ 2016-02-04 ）[ 2024-09-18 ] . https：//www.ema.europa.eu/en/documents/presentation/presentation-how-european-medicines-agency-interacts-patients-consumers_en.pdf https://www.ema.europa.eu/en/documents/presentation/presentation-how-european-medicines-agency-interacts-patients-consumers_en.pdf .

EMA . Getting involved in EMA activities as a patient，consumer or career [EB/OL ] . （ 2024-07-11 ）[ 2024-11-06 ] . https：//www.ema.europa.eu/en/partners-networks/patients-consumers/getting-involved-ema-activities-patient-consumer-or-career#overview-of-patient-involvement-along-the-medicines-lifecycle-at-ema-38705 https://www.ema.europa.eu/en/partners-networks/patients-consumers/getting-involved-ema-activities-patient-consumer-or-career#overview-of-patient-involvement-along-the-medicines-lifecycle-at-ema-38705 .

EMA . EU innovation network （EU-IN） [EB/OL ] .（ 2020-06-12 ）[ 2024-09-18 ] . https：//www.ema.europa.eu/en/committees/working-parties-other-groups/eu-innovation-network-eu https://www.ema.europa.eu/en/committees/working-parties-other-groups/eu-innovation-network-eu .

PPI Japan . Organization overview [EB/OL ] . （ 2023-01-01 ）[ 2024-09-18 ] . https：//www.ppijapan.org/about https://www.ppijapan.org/about .

OGOURTSOVA T ， GONZALEZ M ， ZERBO A ， et al . Lessons learned in measuring patient engagement in a Canada-wide childhood disability network [J ] . Res Involv Engagem ， 2024 ， 10 （ 1 ）： 18 .

人民日报 . “淋巴瘤之家”创始人顾洪飞：让患者组织助力政策落地 [EB/OL ] . （ 2022-11-19 ）[ 2025-01-09 ] . https：//m.peopledailyhealth.com/articleDetailShare articleId=8edf7bd3b28e450aba76e4922bfa29da https://m.peopledailyhealth.com/articleDetailSharearticleId=8edf7bd3b28e450aba76e4922bfa29da .

罕见病信息网 . 中国患者社群组织参与药物研发的现状 [EB/OL ] . （ 2023-03-28 ）[ 2024-9-11 ] . https：//mp.weixin.qq.com/s/r0eW2mVBxjmaH8QR65m0Tg https://mp.weixin.qq.com/s/r0eW2mVBxjmaH8QR65m0Tg .

范子田 . “患者参与”：医疗变革特效药 [J ] . 中国医院院长， 2015 ， 11 （ 3 ）： 86 - 88 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

澳大利亚药品可及性政策介绍及对我国的启示 ^Δ

英国NICE卫生技术评估公众参与机制及启示

国外药品生产远程检查模式介绍及启示

台湾地区医院药学模式介绍及对大陆地区的启示

国外客观结构化临床考试在药学临床技能评估中的应用及对我国的启示